• TNFα, VASN, and Glioma Stem-Cell Self-Renewal

  2026-10-13

  A 2024 Neuro-Oncology study links low tumor-necrosis-factor α signaling with glioma stem-cell self-renewal through a VASN-associated glycolytic feedback loop. The findings are mechanistically suggestive but remain preclinical and do not establish a clinical treatment strategy.

• G007-LK in HCC: Findings and Limits

  2026-10-13

  The 2017 Jia et al. study links tankyrase inhibition with reduced hepatocellular carcinoma cell growth and altered Hippo–YAP signaling, but its cell-based design limits conclusions about clinical activity, tumor selectivity, and applicability beyond the tested models.

• Transcription Termination and WEE1-Linked DNA Damage

  2026-10-12

  A 2026 Nucleic Acids Research study examines how transcription termination limits DNA damage after WEE1 inhibition. Its findings support a role for read-through transcription and transcription–replication conflicts in replication-associated genome instability, while remaining preclinical and mechanistically bounded.

• Schwartz’s Framework for Measuring Cancer Drug Response

  2026-10-12

  A source-grounded overview of Hannah R. Schwartz’s dissertation on distinguishing growth inhibition from cell death in in vitro cancer drug-response measurements, with limits on applying its conclusions to Pazopanib Hydrochloride or clinical care.

• Bifurcated Redox Sensing by TRPV1 and TRPA1

  2026-10-10

  A 2026 Redox Biology study shows that TRPV1 and TRPA1 do not respond to reactive oxygen species uniformly: each channel distinguishes singlet oxygen from hydrogen peroxide through different functional and molecular responses. The findings refine models of redox signaling by linking ROS identity, channel subtype, agonist state, and candidate amino-acid modifications.

• 2-Hydroxypropyl-β-cyclodextrin Product Overview

  2026-10-09

  Supplier-reported identity and conceptual scope for 2-Hydroxypropyl-β-cyclodextrin (SKU B6413), with no matched paper evidence available to establish performance or broader applicability.

• Mianserin HCl: Evidence, Uses, and Limits

  2026-10-09

  Mianserin HCl is a tetracyclic antidepressant research compound and historical 5-HT2 receptor antagonist. A small, short placebo-controlled inpatient study reported improvements in depressive symptoms and sleep, but concurrent sedative treatment and limited follow-up constrain interpretation. Additional antiparasitic and cyclodextrin-complex claims remain preliminary in the supplied evidence.

• CAR-M Immunotherapy in HCC: Evidence and Limits

  2026-10-08

  A source-grounded overview of a 2026 preclinical study developing an in situ generated CAR macrophage for hepatocellular carcinoma. The article explains the study’s rationale, reported findings, evidence comparisons, translational significance and limitations, while clarifying that the supplied evidence does not establish a role for Anti-CD4 Antibody (Ibalizumab) in this CAR-M strategy.

• PDK4-IN-1 Hydrochloride: From Target to Translation

  2026-10-08

  PDK4-IN-1 hydrochloride offers a selective framework for examining how PDK4-dependent control of PDH reshapes mitochondrial metabolism. This thought-leadership perspective connects the 2019 discovery study with translational questions around metabolic disease, cardiac biology, tumor research, evidence quality, and compound provenance.

• ROS-Responsive mRNA Delivery for Mutant RAS Tumors

  2026-10-07

  Cai and colleagues developed a combinatorial library of ROS-degradable lipid nanoparticles and identified BAmP-TK-12 as a carrier that preferentially enhanced mRNA delivery in tumor cells. The study further used DUF5-encoding mRNA to disrupt mutant RAS signaling, providing proof-of-concept for disease-state-responsive mRNA therapeutics while leaving important questions about mechanism, safety, and clinical transferability unresolved.

• ZNF263, STAT3, and Chemoradiotherapy Resistance in CRC

  2026-10-07

  A 2024 Scientific Reports study links elevated ZNF263 with colorectal cancer progression, a STAT3-centered regulatory mechanism, and greater chemoradiotherapy resistance. The findings support ZNF263 as a candidate biomarker and mechanistic target for further validation, but the evidence remains primarily associative and cell-model based rather than clinically actionable.

• PARP7, STAT1/2, and EAE: Key Study Insights

  2026-10-06

  Xu et al. identify PARP7 as a suppressor of type I interferon signaling that promotes STAT1 and STAT2 modification, ubiquitination, and p62-associated autophagic degradation. Their mouse EAE findings connect this mechanism to reduced disease severity, while also underscoring the limits of translating an autoimmune disease model directly to multiple sclerosis therapy.

• TG003: Linking Clk2 to Splicing and Cancer

  2026-10-06

  TG003 is a Cdc2-like kinase inhibitor that connects kinase pharmacology with alternative splicing and cancer biology. This evidence-focused review examines what TG003 can reveal about Clk signaling, how the 2024 CLK2–BRCA1 study changes interpretation, and where translational boundaries remain.

• Doxycycline: Research Context and Evidence

  2026-10-05

  Doxycycline is a tetracycline antibiotic used in antimicrobial, host-response, metalloproteinase, gene-regulation, and cancer research. This overview separates established pharmacology from exploratory applications, compares evidence across cellular, animal, and clinical settings, and explains why antiproliferative findings should not be interpreted as proof of anticancer efficacy. It also distinguishes doxycycline from doxorubicin, the drug examined in the supplied nanocarrier study, and outlines important limitations involving exposure, tissue distribution, mitochondrial effects, microbiome changes, and model relevance.

• Cell Integrity and Ploidy Limits in Budding Yeast

  2026-10-05

  Barker, Murray, and Bell show that budding yeast can reach approximately 32–64C DNA content through repeated genome duplication, but that ploidy is constrained by cell-surface integrity rather than by chromosome content alone. The study connects increasing cell size and surface stress with an upper limit to polyploidy and identifies repression of ergosterol-biosynthesis genes as a molecular correlate, while leaving direct translational and antifungal implications open.

8381 records 1/559 page Next 12345 下5页 Last page